BCMA-Targeted Immunotherapy for Multiple Myeloma

Authors

Bo Yu
Tianbo Jiang
Delong Liu, New York Medical CollegeFollow

DOI

10.1186/s13045-020-00962-7

Journal Title

Journal of Hematology and Oncology

First Page

125

Last Page

125

Document Type

Review Article

Publication Date

9-17-2020

Department

Medicine

Keywords

Antibodies, Bispecific, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, B-Cell Maturation Antigen, B-Lymphocytes, Clinical Trials as Topic, Humans, Immunoconjugates, Immunotherapy, Immunotherapy, Adoptive, Molecular Targeted Therapy, Multicenter Studies as Topic, Multiple Myeloma, Neoplasm Proteins, Plasma Cells, Protein Isoforms, Randomized Controlled Trials as Topic

Disciplines

Medicine and Health Sciences

Abstract

B cell maturation antigen (BCMA) is a novel treatment target for multiple myeloma (MM) due to its highly selective expression in malignant plasma cells (PCs). Multiple BCMA-targeted therapeutics, including antibody-drug conjugates (ADC), chimeric antigen receptor (CAR)-T cells, and bispecific T cell engagers (BiTE), have achieved remarkable clinical response in patients with relapsed and refractory MM. Belantamab mafodotin-blmf (GSK2857916), a BCMA-targeted ADC, has just been approved for highly refractory MM. In this article, we summarized the molecular and physiological properties of BCMA as well as BCMA-targeted immunotherapeutic agents in different stages of clinical development.

Recommended Citation

Yu, B., Jiang, T., & Liu, D. (2020). BCMA-Targeted Immunotherapy for Multiple Myeloma. Journal of Hematology and Oncology, 13 (1), 125-125. https://doi.org/10.1186/s13045-020-00962-7